{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:25:45Z","timestamp":1764242745916,"version":"3.46.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["Sanofi"],"award-info":[{"award-number":["Sanofi"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fabry disease (FD; OMIM # 301500) is a rare, X-linked lysosomal storage disorder caused by mutations in the \u03b1-galactosidase A (\n                      <jats:italic>GLA<\/jats:italic>\n                      ) gene. Deficiency or absence of alpha-galactosidase A (\u03b1-Gal A) enzyme activity leads to the accumulation of glycosphingolipids, specifically globotriaosylceramide (GL-3), in lysosomes leading to various symptoms and signs such as neuropathic pain, gastrointestinal manifestations, renal failure, hypertrophic cardiomyopathy and fibrosis, cardiac rhythm disturbances, heart failure, and stroke. This observational study aimed to describe the journey of patients to FD diagnosis (symptoms, comorbidities, related diagnoses, tests, procedures, and healthcare resource utilization) by assessing data from two US claims databases (Optum Clinformatics\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Data Mart [Optum CDM] database and Komodo Research Dataset [Komodo RD]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study population consisted of 201 patients from the Optum CDM database and 923 patients from the Komodo RD. The mean (SD) age of patients on the index date was 56.0 (20.0) years in the Optum CDM database and 40.5 (21.6) years in the Komodo RD. In the baseline (two years prior to first observed FD diagnosis or treatment) patients had a high prevalence of cardiovascular (72.6% Optum CDM, 56.4% Komodo RD), neurologic (64.2% Optum CDM, 59.3% Komodo RD), gastrointestinal (46.3% Optum CDM, 51.2% Komodo RD), and mental health (32.8% Optum CDM, 36.5% Komodo RD) clinical symptoms and comorbidities. Females showed a higher prevalence of mental health conditions compared to males across both databases. Neurologic and cardiovascular medications were the most commonly prescribed medication classes across both databases (neurologic: 61.2% in both cohorts; cardiovascular: 60.7% Optum CDM, 50.6% Komodo RD). In terms of provider specialty, a high proportion of patients represented in the Optum CDM cohort had claims from family &amp; preventive medicine (73.1%), radiology (72.1%), and internal medicine (61.2%) during the 2 years prior to FD diagnosis. Per Komodo RD, patients had claims from general practitioners (87.4%), radiologists (63.4%), emergency medicine specialists (57.0%) and anesthesiologists (25.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study assessed the journey of patients with FD to diagnosis based on two large US claims databases, Optum CDM and Komodo RD. The results highlighted a significant burden of cardiovascular, neurologic, and gastrointestinal symptoms and comorbidities, along with associated medication use, in the two years prior to diagnosis. Identifying these comorbidity profiles in patients with FD could shorten time to diagnosis and provide improved disease management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04041-3","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:21:40Z","timestamp":1764242500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient journey to Fabry disease diagnosis in the United States: an observational retrospective analysis of two United States claims databases"],"prefix":"10.1186","volume":"20","author":[{"given":"Alexandra","family":"Dumitriu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gandarvaka","family":"Miles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Maksimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Queeny","family":"Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Leiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiange","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Petruski-Ivleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"4041_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. https:\/\/doi.org\/10.1186\/1750-1172-5-30.","journal-title":"Orphanet J Rare Dis"},{"key":"4041_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2024.101891","volume":"2","author":"DA Laney","year":"2024","unstructured":"Laney DA, Houde MF, Foley AL, Peck DS, Atherton AM, Manwaring LP, et al. Prospective characterization of early symptom onset and progression in young pediatric patients with variants in the GLA gene across 5 years: longitudinal data from the Fabry moppet study. Genet Med Open. 2024;2:101891. https:\/\/doi.org\/10.1016\/j.gimo.2024.101891.","journal-title":"Genet Med Open"},{"issue":"4","key":"4041_CR3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327. https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4041_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340. https:\/\/doi.org\/10.1086\/504601.","journal-title":"Am J Hum Genet"},{"issue":"10","key":"4041_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936\u2009+\u2009919G\u2009>\u2009A (IVS4\u2009+\u2009919G\u2009>\u2009A). Hum Mutat. 2009;30(10):1397\u2013405. https:\/\/doi.org\/10.1002\/humu.21074.","journal-title":"Hum Mutat"},{"issue":"4","key":"4041_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jmg-2022-108523","volume":"60","author":"M Gilchrist","year":"2023","unstructured":"Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, et al. Prevalence of Fabry disease-causing variants in the UK biobank. J Med Genet. 2023;60(4):391\u20136. https:\/\/doi.org\/10.1136\/jmg-2022-108523.","journal-title":"J Med Genet"},{"issue":"6","key":"4041_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","volume":"360","author":"M Michaud","year":"2020","unstructured":"Michaud M, Mauhin W, Belmatoug N, Garnotel R, Bedreddine N, Catros F, et al. When and how to diagnose Fabry disease in clinical pratice. Am J Med Sci. 2020;360(6):641\u20139. https:\/\/doi.org\/10.1016\/j.amjms.2020.07.011.","journal-title":"Am J Med Sci"},{"issue":"3","key":"4041_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203. https:\/\/doi.org\/10.1016\/j.ymgme.2018.06.004.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4041_CR9","doi-asserted-by":"publisher","first-page":"e37048","DOI":"10.7759\/cureus.37048","volume":"15","author":"SM Besekar","year":"2023","unstructured":"Besekar SM, Jogdand SD, Naqvi WM. Fabry disease and its management: a literature analysis. Cureus. 2023;15(4):e37048. https:\/\/doi.org\/10.7759\/cureus.37048.","journal-title":"Cureus"},{"issue":"11","key":"4041_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769\u201375. https:\/\/doi.org\/10.1136\/jmg.38.11.769.","journal-title":"J Med Genet"},{"issue":"2","key":"4041_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab. 2008;93(2):112\u201328. https:\/\/doi.org\/10.1016\/j.ymgme.2007.09.013.","journal-title":"Mol Genet Metab"},{"key":"4041_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.gene.2017.10.064","volume":"641","author":"P Juchniewicz","year":"2018","unstructured":"Juchniewicz P, Kloska A, Tylki-Szyma\u0144ska A, Jak\u00f3bkiewicz-Banecka J, W\u0119grzyn G, Moskot M, et al. Female Fabry disease patients and X-chromosome inactivation. Gene. 2018;641:259\u201364. https:\/\/doi.org\/10.1016\/j.gene.2017.10.064.","journal-title":"Gene"},{"key":"4041_CR13","unstructured":"FABRAZYME. US Prescribing Information. Accessed August 15. 2024. https:\/\/products.sanofi.us\/Fabrazyme\/Fabrazyme.pdf"},{"key":"4041_CR14","unstructured":"ELFABRIO. US Prescribing Information. Accessed May 15. 2024. https:\/\/resources.chiesiusa.com\/Elfabrio\/ELFABRIO_PI.pdf"},{"key":"4041_CR15","unstructured":"GALAFOLD. US Prescribing Information. Accessed April 15. 2025. https:\/\/www.amicusrx.com\/pi\/galafold.pdf"},{"key":"4041_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.640876","volume":"8","author":"Y Battaglia","year":"2021","unstructured":"Battaglia Y, Fiorini F, Azzini C, Esposito P, De Vito A, Granata A, et al. Deficiency in the screening process of Fabry disease: analysis of chronic kidney patients not on dialysis. Front Med Lausanne. 2021;8:640876. https:\/\/doi.org\/10.3389\/fmed.2021.640876.","journal-title":"Front Med Lausanne"},{"issue":"5","key":"4041_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jpeds.2010.02.012","volume":"156","author":"CL Marchesoni","year":"2010","unstructured":"Marchesoni CL, Roa N, Pardal AM, Neumann P, C\u00e1ceres G, Mart\u00ednez P, et al. Misdiagnosis in Fabry disease. J Pediatr. 2010;156(5):828\u201331. https:\/\/doi.org\/10.1016\/j.jpeds.2010.02.012.","journal-title":"J Pediatr"},{"issue":"12","key":"4041_CR18","doi-asserted-by":"publisher","first-page":"e0244279","DOI":"10.1371\/journal.pone.0244279","volume":"15","author":"E Mengel","year":"2020","unstructured":"Mengel E, Gaedeke J, Gothe H, Krupka S, Lachmann A, Reinke J, et al. The patient journey of patients with Fabry disease, gaucher disease and mucopolysaccharidosis type II: a German-wide telephone survey. PLoS ONE. 2020;15(12):e0244279. https:\/\/doi.org\/10.1371\/journal.pone.0244279.","journal-title":"PLoS ONE"},{"key":"4041_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100909","volume":"33","author":"M Tsurumi","year":"2022","unstructured":"Tsurumi M, Ozaki A, Eto Y. A survey on the patient journey in Fabry disease in Japan. Mol Genet Metab Rep. 2022;33:100909. https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100909.","journal-title":"Mol Genet Metab Rep"},{"issue":"18","key":"4041_CR20","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370\u20135. https:\/\/doi.org\/10.1001\/jama.285.18.2370.","journal-title":"JAMA"},{"issue":"2","key":"4041_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","volume":"114","author":"Y Miyasaka","year":"2006","unstructured":"Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119\u201325. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.595140.","journal-title":"Circulation"},{"issue":"1","key":"4041_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"2","key":"4041_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","volume":"96","author":"DP Germain","year":"2019","unstructured":"Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019;96(2):107\u201317. https:\/\/doi.org\/10.1111\/cge.13546.","journal-title":"Clin Genet"},{"issue":"1","key":"4041_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/jmd2.12071","volume":"49","author":"AM Martins","year":"2019","unstructured":"Martins AM, Cabrera G, Molt F, Su\u00e1rez-Obando F, Vald\u00e9s RA, Varas C, et al. The clinical profiles of female patients with Fabry disease in Latin America: a Fabry registry analysis of natural history data from 169 patients based on enzyme replacement therapy status. JIMD Rep. 2019;49(1):107\u201317. https:\/\/doi.org\/10.1002\/jmd2.12071.","journal-title":"JIMD Rep"},{"issue":"4","key":"4041_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","volume":"55","author":"D Doheny","year":"2018","unstructured":"Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017. J Med Genet. 2018;55(4):261\u20138.","journal-title":"J Med Genet"},{"issue":"4","key":"4041_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/eurheartj\/ehae747","volume":"46","author":"P Elliott","year":"2025","unstructured":"Elliott P, Schunkert H, Bondue A, Behr E, Carrier L, Van Duijn C, et al. Integration of genetic testing into diagnostic pathways for cardiomyopathies: a clinical consensus statement by the ESC council on cardiovascular genomics. Eur Heart J. 2025;46(4):344\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehae747.","journal-title":"Eur Heart J"},{"issue":"7","key":"4041_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1056\/NEJMra2308577","volume":"391","author":"A Vivante","year":"2024","unstructured":"Vivante A. Genetics of chronic kidney disease. N Engl J Med. 2024;391(7):627\u201339. https:\/\/doi.org\/10.1056\/NEJMra2308577.","journal-title":"N Engl J Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04041-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04041-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04041-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:21:41Z","timestamp":1764242501000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04041-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4041"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04041-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RA, NP, AC, IM, GM and AD: Employed at Sanofi and hold company stocks. TY: Is an employee of Genesis Research Group. CL: No conflict of interest. QI and MJ: No conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"613"}}